Next Article in Journal
In Silico Evaluation of the Biopharmaceutical and Pharmacokinetic Behavior of Metronidazole from Coated Colonic Release Matrix Tablets
Previous Article in Journal
Evaluating Immune Activation Feasibility in Pancreatic Ductal Adenocarcinoma via Oxygen Bubble-Induced Anti-Vascular Therapy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: AlMotwaa, S.M.; Al-Otaibi, W.A. Gemcitabine-Loaded Nanocarrier of Essential Oil from Pulicaria crispa: Preparation, Optimization, and In Vitro Evaluation of Anticancer Activity. Pharmaceutics 2022, 14, 1336

by
Sahar M. AlMotwaa
*,† and
Waad A. Al-Otaibi
Department of Chemistry, College of Science and Humanities, Shaqra University, P.O. Box 6974, Al Quwayiyah 19257, Saudi Arabia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceutics 2025, 17(5), 646; https://doi.org/10.3390/pharmaceutics17050646
Submission received: 3 April 2025 / Revised: 27 April 2025 / Accepted: 8 May 2025 / Published: 14 May 2025
Error in Figure
In the original publication [1], there was a mistake in Figure 8 as published. Figure 8G–H was duplicated incorrectly in the proof version. The corrected Figure 8H appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. AlMotwaa, S.M.; Al-Otaibi, W.A. Gemcitabine-Loaded Nanocarrier of Essential Oil from Pulicaria crispa: Preparation, Optimization, and In Vitro Evaluation of Anticancer Activity. Pharmaceutics 2022, 14, 1336. [Google Scholar] [CrossRef] [PubMed]
Figure 8. Effect of PC-NE and PC-NE:GEM on apoptosis of MCF-7 and Hep-G2 cells, as was estimated with Annexin V-FITC-PI staining and flow cytometry. (A) MCF-7 control cells; (B) MCF-7 cells treated with 0.3 μM GEM; (C) MCF-7 cells treated with 0.3% v/v PC-NE; (D) MCF-7 cells treated with PC-NE:GEM (0.3% (v/v) + 0.3 μM); (E) Hep-G2 control cells; (F) Hep-G2 cells treated with 0.5 μM GEM; (G) Hep-G2 cells treated with 0.5% (v/v) PC-NE; (H) Hep-G2 cells treated with PC-NE:GEM (0.5% (v/v) + 0.5 μM). (I) Percentages of apoptosis (early plus late) in MCF-7 and Hep-G2 cells. The statistical differences were determined by independent sample t-test, one-way ANOVA, and Tukey’s post hoc test. The data are expressed as mean ± SEM (n = 3); *** p  <  0.001; ns = not significant.
Figure 8. Effect of PC-NE and PC-NE:GEM on apoptosis of MCF-7 and Hep-G2 cells, as was estimated with Annexin V-FITC-PI staining and flow cytometry. (A) MCF-7 control cells; (B) MCF-7 cells treated with 0.3 μM GEM; (C) MCF-7 cells treated with 0.3% v/v PC-NE; (D) MCF-7 cells treated with PC-NE:GEM (0.3% (v/v) + 0.3 μM); (E) Hep-G2 control cells; (F) Hep-G2 cells treated with 0.5 μM GEM; (G) Hep-G2 cells treated with 0.5% (v/v) PC-NE; (H) Hep-G2 cells treated with PC-NE:GEM (0.5% (v/v) + 0.5 μM). (I) Percentages of apoptosis (early plus late) in MCF-7 and Hep-G2 cells. The statistical differences were determined by independent sample t-test, one-way ANOVA, and Tukey’s post hoc test. The data are expressed as mean ± SEM (n = 3); *** p  <  0.001; ns = not significant.
Pharmaceutics 17 00646 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

AlMotwaa, S.M.; Al-Otaibi, W.A. Correction: AlMotwaa, S.M.; Al-Otaibi, W.A. Gemcitabine-Loaded Nanocarrier of Essential Oil from Pulicaria crispa: Preparation, Optimization, and In Vitro Evaluation of Anticancer Activity. Pharmaceutics 2022, 14, 1336. Pharmaceutics 2025, 17, 646. https://doi.org/10.3390/pharmaceutics17050646

AMA Style

AlMotwaa SM, Al-Otaibi WA. Correction: AlMotwaa, S.M.; Al-Otaibi, W.A. Gemcitabine-Loaded Nanocarrier of Essential Oil from Pulicaria crispa: Preparation, Optimization, and In Vitro Evaluation of Anticancer Activity. Pharmaceutics 2022, 14, 1336. Pharmaceutics. 2025; 17(5):646. https://doi.org/10.3390/pharmaceutics17050646

Chicago/Turabian Style

AlMotwaa, Sahar M., and Waad A. Al-Otaibi. 2025. "Correction: AlMotwaa, S.M.; Al-Otaibi, W.A. Gemcitabine-Loaded Nanocarrier of Essential Oil from Pulicaria crispa: Preparation, Optimization, and In Vitro Evaluation of Anticancer Activity. Pharmaceutics 2022, 14, 1336" Pharmaceutics 17, no. 5: 646. https://doi.org/10.3390/pharmaceutics17050646

APA Style

AlMotwaa, S. M., & Al-Otaibi, W. A. (2025). Correction: AlMotwaa, S.M.; Al-Otaibi, W.A. Gemcitabine-Loaded Nanocarrier of Essential Oil from Pulicaria crispa: Preparation, Optimization, and In Vitro Evaluation of Anticancer Activity. Pharmaceutics 2022, 14, 1336. Pharmaceutics, 17(5), 646. https://doi.org/10.3390/pharmaceutics17050646

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop